Clinical Trial Update: Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and tolerability of IC83/LY2603618 after pemetrexed in cancer patients; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• IC83/LY2603618 (IC83/LY2603618)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Cancer | Phase 1 | Status: COMPLETED | Results posted: 2018-10-19